JAMA · 1990 · 247 citations · 40 references
MedicineOncologyPreventive MedicineCancer EpidemiologyCancer PreventionWomen's HealthBreast Cancer Risk AssessmentCancer RiskMenopause Hormone TherapyMenopause ManagementAge-specific Risk AssessmentBreast Cancer HistoryCancer Incidence EpidemiologyCumulative Cancer IncidenceRelative Risk Estimation
We prospectively examined the use of estrogen replacement therapy in relation to breast cancer incidence in a cohort of women 30 to 55 years of age in 1976. During 367 187 person-years of follow-up among postmenopausal women, 722 incident cases of breast cancer were documented. Overall, past users of replacement estrogen were not at increased risk (relative risk, 0.98; 95% confidence interval, 0.81 to 1.18), including even those with more than 10 years since last [corrected] use (relative risk after adjustment for established risk factors, 0.70; 95% confidence interval, 0.45 to 1.10). However, the risk of breast cancer was significantly elevated among current users (relative risk, 1.36; 95% confidence interval, 1.11 to 1.67). Among current users, a stronger relationship was observed with increasing age but not with increasing duration of use. These data suggest that long-term past use of estrogen replacement therapy is not related to risk of breast cancer but that current use may modestly increase risk.
40
REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY
Làszló Tabár, Ahmed Z. Gad, Lars Holmberg et al. · The Lancet · 1985 · 1.8K citations
Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.
Ingvar Andersson, Knut Aspegren, Lars Janzon et al. · BMJ · 1988 · 926 citations · Full text